REATA PHARMACEUTICALS INC
REATA PHARMACEUTICALS INC (RETA): 4 pipeline candidates · ~15 mo cash runway. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
14.5 months
N/A
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for REATA PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$48.8M
Quarterly Burn
$69.9M
Runway
14.5 mo
Revenue
$22.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| bardoxolone | Phase 3 |
| cemdomespib | Phase 2 |
| risperidone | Approved |
| rta 901 | Phase 2 |
Frequently asked questions
How many drug candidates are in REATA PHARMACEUTICALS INC's pipeline?
REATA PHARMACEUTICALS INC (RETA) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is REATA PHARMACEUTICALS INC's lead drug candidate?
REATA PHARMACEUTICALS INC's most advanced tracked candidate is bardoxolone (Phase 3) for Chronic kidney disease (CKD) caused by Alport syndrome, autosomal dominant polycystic kidney disease (ADPKD), and type 1 and 2 diabetic CKD.
What is REATA PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, REATA PHARMACEUTICALS INC has approximately 14.5 months of cash runway.
Who is the CEO of REATA PHARMACEUTICALS INC?
Warren Huff is the chief executive officer of REATA PHARMACEUTICALS INC (RETA).
Get the full picture on REATA PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.